Medication info
Hanwha Lorkan Tablet 10/16mg (Rosuvastatin Calcium, Candesartan Cilexetil)

Hanwha Lorkan Tablet 10/16mg (Rosuvastatin Calcium, Candesartan Cilexetil)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tabletCandesartan Cilexetil›16mg / 1 tablet
Manufacturer / importer
Hanwha Pharmaceutical Co., Ltd.
Appearance
Yellow round film-coated tablet
Packaging
30 tablets (10 tablets/PTP X 3)
Approval status
Active

MFDS item code 202301657 · Approved 2023.05.24 · Insurance code 651602900

Summary

Main use
Treatment of dyslipidemia, hypertension, and heart failure; inhibition of atherosclerosis progression; prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
This drug is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil/rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose in patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. There is limited experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min). 5) Patients with hepatic impairment: The initial dose in patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout treatment. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this drug to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience in patients with a Child-Pugh score above 9. Do not administer this drug to patients with active liver disease. 5. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligram dose of this drug is contraindicated in some of these patients. For patients taking candesartan cilexetil and rosuvastatin concomitantly, they may switch to this drug (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
Adolescents and children 18 years of age or younger: Safety and efficacy have not been established. Adolescents and children 18 years of age or younger: Safety and efficacy have not been established.

Ingredients

Manufacturer
Hanwha Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, hypertension, and heart failure; inhibition of atherosclerosis progression; prevention of cardiovascular disease

  • Essential hypertension
  • heart failure
  • impaired left ventricular systolic function
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol
View approved original text

This medication is used for patients who need to take both Candesartan Cilexetil and Rosuvastatin. Candesartan Cilexetil treats hypertension and aids heart failure patients with impaired left ventricular systolic function when there are restrictions on ACE inhibitors or additional therapy is needed. Meanwhile, Rosuvastatin is used with dietary therapy for patients with hypercholesterolemia or dyslipidemia to control cholesterol levels and slow the progression of arteriosclerosis. It may also reduce the risks of stroke, myocardial infarction, and vascular revascularization in patients at high risk of cardiovascular disease. Therefore, this medication improves hypertension and heart failure alongside cholesterol control and reduces cardiovascular disease risk.

How to take

Adult dose

This drug is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil/rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose in patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. There is limited experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min). 5) Patients with hepatic impairment: The initial dose in patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout treatment. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this drug to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience in patients with a Child-Pugh score above 9. Do not administer this drug to patients with active liver disease. 5. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligram dose of this drug is contraindicated in some of these patients. For patients taking candesartan cilexetil and rosuvastatin concomitantly, they may switch to this drug (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

Adolescents and children 18 years of age or younger: Safety and efficacy have not been established. Adolescents and children 18 years of age or younger: Safety and efficacy have not been established.

Precautions

This medication can cause serious harm to the fetus and newborn if administered to pregnant women, so it should be discontinued immediately if pregnancy is confirmed. Patients with allergic reactions to this medication, severely impaired liver function, pregnant or breastfeeding women, and those with certain kidney or muscle disorders should not use it. Elderly patients or those with mildly impaired liver function, high serum potassium levels, and others should use this medication cautiously, and regular checks of liver function and muscle health should be conducted during treatment. Muscle-related side effects such as muscle pain or weakness may occur, so if symptoms like muscle pain, cramps, or weakness appear, consult a doctor immediately. Additionally, since this medication may affect liver function, treatment should be stopped immediately if symptoms of hepatitis or jaundice occur, and medical attention should be sought. This medication can interact with other drugs, so anyone currently taking other medications should inform their doctor or pharmacist, particularly when combined with potassium-sparing diuretics, certain antibiotics, or antifungal medications. Women planning to become pregnant should consult a doctor before taking this medication and use appropriate contraceptive methods. Breastfeeding mothers should also avoid taking this medication. The safety and efficacy of this medication in children have not been established; therefore, its use is not recommended. In cases of overdose, appropriate treatment is required based on symptoms, and this medication is not removed by blood dialysis, so no specific detoxification method exists. Finally, this medication should be kept out of reach of children and stored in the original container to prevent misuse.

Side effects

Headache, rhinitis, local infection, chest discomfort, fatigue, inflammation, generalized pruritus, dermatitis, itching, joint stiffness, musculoskeletal pain, neck pain, limb pain, cataract, photophobia, dyspepsia, nausea, increased blood sugar, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, tooth extraction, dizziness, positional dizziness, molluscum contagiosum, periodontitis, increased blood pressure, orthostatic hypotension, cerebral infarction, spondylitis with myelopathy, musculoskeletal discomfort, pneumonia, femur fracture, contusion, unstable angina, idiopathic pulmonary fibrosis, wet cough, exacerbation of hypertension, unstable blood pressure, vertigo, positional vertigo, adrenal insufficiency, vascular edema, low back pain, respiratory infection, upper respiratory infection, pharyngitis, rhinitis, myasthenia, fever, paresthesia, dyspepsia, gastroenteritis, tachycardia, palpitations, increased creatine kinase, hyperglycemia, hypertriglyceridemia, hyperuricemia, myalgia, epistaxis, anxiety, depression, somnolence, dyspnea, rash, increased sweating, hematuria, polyneuropathy, memory loss, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, edema, depression, sleep disorder, insomnia, nightmares, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive decline, forgetfulness, amnesia, memory impairment, confusion, severe myasthenia, ocular myasthenia, constipation, abdominal pain, pancreatitis, myopathy, myositis, rhabdomyolysis, myasthenia, bowel vascular edema, gastrointestinal swelling, thirst, sleep disorder, decreased libido, forgetfulness, loss of appetite, increased appetite, tinnitus, taste distortion, erectile dysfunction, joint pain, numbness, sensory disturbance, chest discomfort, abdominal distension, syncope, generalized pain, muscle cramps, gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. Additionally, it should be stored at room temperature between 1 to 30 degrees Celsius for optimal effectiveness.

Appearance and packaging

Appearance

Yellow round film-coated tablet

Package unit

30 tablets (10 tablets/PTP X 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.